Positives

• A case report in the Cardiopulmonary Physical Therapy Journal documented marked symptom improvement in a Long COVID patient treated with enoxaparin 20 mg/day subcutaneously, assessed at 8 weeks Cardiopulmonary Physical Therapy Journal.
  
  
• A separate personal account noted that within a few weeks of starting subcutaneous enoxaparin, activity levels improved and all Long COVID symptoms began to decrease, in line with the microclot-removal hypothesis Positive Nutrition.
  
  

Negatives

• A patient who took twice-daily Lovenox for eight months after an injury described having to constantly rotate from stomach to rump because after 4-5 days the sites were “covered in bruises,” calling it “a really awful experience to go through”.
• WebMD reviewers of enoxaparin frequently report painful injection sites, large bruising, and burning that lasts hours, with several patients saying daily injections wore them down even when they understood the clot risk WebMD.

Hurdles & Side Effects

• Enoxaparin requires daily subcutaneous self-injection and carries the standard heparin risks of bleeding, heparin-induced thrombocytopenia, and injection-site bruising; patients usually need a hematologist or sympathetic GP willing to monitor for off-label Long COVID use NIH.
  
  
• Brand-name Lovenox is expensive (roughly $700-1,000/month for prophylactic dosing); generic enoxaparin costs much less but still requires a prescription and is not covered by most insurance for Long COVID without a documented clotting disorder PMC.